The latest biotech scorecard from STAT outlines 23 critical events anticipated in the second quarter that may influence stock performance within the industry.
These events are essential for stakeholders to monitor, as they could affect market dynamics and investment strategies.
Understanding the implications of these events is crucial for assessing infrastructure capacity and operational readiness in the biotech sector.